.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J04A_DrugsForTreatmentOfTuberculosis.J04AB04_Rifabutin.Rifabutin

Information

Rifabutin is a rifamycin antibiotic used primarily for the prevention and treatment of Mycobacterium avium complex (MAC) infections, particularly in immunocompromised patients such as those with HIV/AIDS. It is approved for use and is also sometimes used as part of multi-drug regimens for tuberculosis and other atypical mycobacterial infections.

Pharmacokinetics

Pharmacokinetic parameters for healthy adult volunteers, oral administration, single dose.

References

1. DeRossi, SS, & Hersh, EV (2002). Antibiotics and oral contraceptives. Dental clinics of North America 46(4) 653–664. DOI:10.1016/s0011-8532(02)00017-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12436822

2. Mirochnick, M, et al., & Spector, SA (2001). Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection. Clinical pharmacology and therapeutics 70(1) 24–32. DOI:10.1067/mcp.2001.115891 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11452241

3. Khalilieh, S, et al., & Iwamoto, M (2020). Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions. Clinical drug investigation 40(10) 927–946. DOI:10.1007/s40261-020-00934-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32816220

Revisions

• 06/2025 initial generated model